Tulobuterol transdermal - NAL Pharma

Drug Profile

Tulobuterol transdermal - NAL Pharma

Alternative Names: NAL 6328

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NAL Pharma
  • Class Antiasthmatics; Bronchodilators
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Respiratory tract disorders

Most Recent Events

  • 12 Dec 2016 Chemical structure information added
  • 29 Nov 2016 Tulobuterol transdermal - NAL Pharma is available for licensing as of 29 Nov 2016. http://www.nalpharma.com/licensing.php?id=7&lang=en
  • 29 Nov 2016 Clinical trials in Respiratory tract disorders (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top